Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17
European Journal of Cancer2015Vol. 51(11), pp. 1405–1414
Citations Over TimeTop 1% of 2015 papers
Stephanie Yasmin Brule, Derek J. Jonker, Christos S. Karapetis, Chris J. O’Callaghan, Malcolm J. Moore, Ralph Wong, Niall C. Tebbutt, Craig Underhill, Desmond Yip, John Zalcberg, Dongsheng Tu, Rachel Goodwin
Related Papers
- → Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer(2006)110 cited
- → Cost-Effectiveness Analysis of KRAS Testing and Cetuximab as Last-Line Therapy for Colorectal Cancer(2010)46 cited
- Evolving role of cetuximab in the treatment of colorectal cancer.(2009)
- → Abstract C43: Dasatinib resensitizes Kras mutant colorectal tumors to cetuximab(2009)1 cited
- → A Case of KRAS Exon 2 Wild Colorectal Cancer Resistant to the Anti-EGFR Therapy(2016)